Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578385/
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels.
SGLT2 inhibitors in patients with diabetes mellitus have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and reducing cardiac mortality.
Impact of SGLT2 Inhibitors on Patient Outcomes: a Network Meta-Analysis
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-02035-8
A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM), heart failure (HF), and chronic kidney...
A network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin.
Kidneys in Heart Failure: Impact of Flozins and Beyond
Source : https://pubmed.ncbi.nlm.nih.gov/37937356/
Chronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related.
SGLT2 inhibitors are cardioprotective in a wide spectrum of eGFR rates, although data for patients with HF with respect to the UAC ratio remain limited.
Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients With Coexistent Heart Failure and Atrial Fibrillation
Source : https://link.springer.com/article/10.1007/s12265-023-10454-x
The coexistence of heart failure (HF) and atrial fibrillation (AF) worsens the prognosis of patients. We aimed to study the inflammation, metabolism, adiposity, and fibrosis markers on epicardial and subcutaneous...
Plasma FABP4 was identified as the main heart failure (HF) predictor. Higher levels of adiposity markers are associated with atrial fibrillation (AF) or HF and higher stretch and fibrosis markers with combined AF and HF.
Cryoballoon Ablation for Atrial Fibrillation in Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction: a Systematic Review and Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37877802/
The coexistence of atrial fibrillation (AF) with heart failure (HF) is prevalent, leading to severe complications.
These study results indicated a noteworthy effect of cryoablation in mitigating atrial fibrillation (AF) recurrence, alongside a success rate, denoted by freedom from AF at 1 and 2 years postprocedure.